• Vaccine Name: Leishmania infantum HSP70 II mutant vaccine
• Target Pathogen: Leishmania infantum
• Target Disease: Infantile visceral leishmaniasis
• Vaccine Ontology ID: VO_0003006
• Type: Live, attenuated vaccine
• Status: Research
• HSP70 II gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: The HSP70-II null mutant (∆hsp70-II::NEO/∆hsp70-II::HYG) is a cloned line that was generated by targeted deletion of both HSP70-II alleles in the L. infantum strain MCAN/ES/96/BCN150 [32]. L. major promastigote (strain MHOM/IL/80/Friedlin; clon V1) were also used in this study. Promastigotes of both species were grown in RPMI 1640 culture medium supplemented with 10% heatinactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (Carrion et al., 2011).
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c mouse
• Persistence: L. infantum parasites lacking the HSP70-II gene have a virulence greatly reduced (Carrion et al., 2011).
• Efficacy: Inoculation of ∆HSP70-II parasites protects BALB/c mice against L. major challenge (Carrion et al., 2011).
• Host Ighv1-9 response
  • Description: The IgG2a titers were high for all groups with differing inoculation routes, suggesting that infection with ΔHSP70-II parasites, independent of the inoculation route, leads to a predominant production of anti-Leishmania antibodies of the IgG2a isotope. Antibody titers were determined by ELISA before and 4 weeks after inoculation and showed an increase between the two samples. IgG2a titers were significantly higher than IgG1 titers (Carrion et al., 2011).
  • Detailed Gene Information: Click Here.